342 related articles for article (PubMed ID: 34768776)
1. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
Pandey MS; Wang C; Umlauf S; Lin S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
[TBL] [Abstract][Full Text] [Related]
2. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
Chen W; Pandey M; Sun H; Rolong A; Cao M; Liu D; Wang J; Zeng L; Hunter A; Lin S
MAbs; 2021; 13(1):1914359. PubMed ID: 33870864
[TBL] [Abstract][Full Text] [Related]
3. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
4. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
5. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
[TBL] [Abstract][Full Text] [Related]
6. T-Cell Engagers Based Bioassay for Evaluation of PD-1/PD-L1 Inhibitors Activity.
Doronin AN; Gordeev AA; Kozlov AE; Smirnova YA; Puchkova MY; Ekimova VM; Basovskiy YI; Solovyev VV
Biochemistry (Mosc); 2019 Jul; 84(7):711-719. PubMed ID: 31509723
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
Chand Dakal T; Dhabhai B; Agarwal D; Gupta R; Nagda G; Meena AR; Dhakar R; Menon A; Mathur R; Mona ; Yadav V; Sharma A
Immunobiology; 2020 Mar; 225(2):151899. PubMed ID: 31899051
[TBL] [Abstract][Full Text] [Related]
9. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
[TBL] [Abstract][Full Text] [Related]
10. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
[TBL] [Abstract][Full Text] [Related]
11. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
12. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
Osada T; Patel SP; Hammond SA; Osada K; Morse MA; Lyerly HK
Cancer Immunol Immunother; 2015 Jun; 64(6):677-88. PubMed ID: 25742933
[TBL] [Abstract][Full Text] [Related]
13. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
14. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
Luangwattananun P; Sangsuwannukul T; Supimon K; Thuwajit C; Chieochansin T; Sa-Nguanraksa D; Samarnthai N; O-Charoenrat P; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2023 Nov; 124(Pt B):111012. PubMed ID: 37804657
[TBL] [Abstract][Full Text] [Related]
16. CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection.
Xu A; Wang R; Freywald A; Stewart K; Tikoo S; Xu J; Zheng C; Xiang J
Biochem Biophys Res Commun; 2017 Mar; 484(3):662-667. PubMed ID: 28153727
[TBL] [Abstract][Full Text] [Related]
17. Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery.
Wu L; Wang W; Tian J; Qi C; Cai Z; Yan W; Xuan S; Shang A
Bioengineered; 2021 Dec; 12(2):12383-12393. PubMed ID: 34895063
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.
Li T; Wang X; Niu M; Wang M; Zhou J; Wu K; Yi M
Front Immunol; 2023; 14():1196970. PubMed ID: 37520520
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules.
Lee HY; Register A; Shim J; Contreras E; Wu Q; Jiang G
MAbs; 2019 Oct; 11(7):1245-1253. PubMed ID: 31348721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]